Agarwal J P, Gupta T, Kalyani N, Budrukkar A, Laskar S G, Murthy V, Kumar P, Narohna V, Pai P, Chaturvedi P, D'cruz A K
Department of Radiation Oncology, Tata Memorial Hospital, Ernest Borges Marg, Parel, Mumbai, India.
Indian J Cancer. 2011 Apr-Jun;48(2):148-53. doi: 10.4103/0019-509X.82872.
To report outcomes of cetuximab concurrent with radiotherapy in advanced head-neck cancer unsuitable for platinum-based chemo-radiotherapy.
Retrospective chart review of 37 patients treated with cetuximab and radiotherapy at a comprehensive cancer centre.
Median age of study cohort was 59 years. Thirty four (92%) patients had advanced stage disease (stage III-IV). Reasons for ineligibility for platinum included impaired creatinine-clearance, old age, and/or co-morbidities. Thirty-two (86%) patients completed planned radiotherapy without interruption; 29 (80%) patients received ≥6 cycles of cetuximab. Fifteen patients (40.5%) developed ≥grade 3 dermatitis; 9 patients (25%) experienced ≥grade 3 mucositis. At a median follow-up of 16 months, the 2-year loco-regional control, disease-free survival, and overall survival was 35.5%, 29.5%, and 44.4% respectively. Stage grouping and severe dermatitis were significant predictors of outcome.
Cetuximab concurrent with radiotherapy is a reasonable alternative in advanced head-neck cancer patients with acceptable compliance and outcomes, but higher skin toxicity.
报告西妥昔单抗联合放疗治疗不适合铂类化疗放疗的晚期头颈癌的疗效。
对一家综合癌症中心37例接受西妥昔单抗和放疗的患者进行回顾性病历审查。
研究队列的中位年龄为59岁。34例（92%）患者患有晚期疾病（III-IV期）。不符合铂类治疗条件的原因包括肌酐清除率受损、年龄较大和/或合并症。32例（86%）患者未中断地完成了计划放疗；29例（80%）患者接受了≥6周期的西妥昔单抗治疗。15例患者（40.5%）发生了≥3级皮炎；9例患者（25%）出现了≥3级黏膜炎。中位随访16个月时，2年局部区域控制率、无病生存率和总生存率分别为35.5%、29.5%和44.4%。分期分组和严重皮炎是结局的重要预测因素。
西妥昔单抗联合放疗对于晚期头颈癌患者是一种合理的替代方案，其依从性和疗效可接受，但皮肤毒性较高。
